Health-Related Quality of Life in Adrenocortical Carcinoma: Development of the Disease-Specific Questionnaire ACC-QOL and Results from the PROFILES Registry.

adrenocortical carcinoma chemotherapy health-related quality of life mitotane questionnaire development

Journal

Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829

Informations de publication

Date de publication:
08 Mar 2022
Historique:
received: 11 01 2022
revised: 28 02 2022
accepted: 02 03 2022
entrez: 25 3 2022
pubmed: 26 3 2022
medline: 26 3 2022
Statut: epublish

Résumé

We aimed to develop a disease-specific adrenocortical carcinoma (ACC) health-related quality of life (HRQoL) questionnaire (ACC-QOL) and assess HRQoL in a population-based cohort of patients with ACC. Development was in line with European Organization for Research and Treatment of Cancer (EORTC) guidelines, though not an EORTC product. In phase I and II, we identified 90 potential HRQoL issues using literature and focus groups, which were reduced to 39 by healthcare professionals. Pilot testing resulted in 28 questions, to be used alongside the EORTC QLQ-C30. In Phase III, 100 patients with ACC were asked to complete the questionnaires twice in the PROFILES registry (3-month interval, respondents: first 67, second 51). Confirmatory factor analysis demonstrated the structural validity of 26 questions with their scale structure (mitotane side-effects, hypercortisolism/hydrocortisone effects, emotional effects). Internal consistency and reliability were good (Cronbach's alpha 0.897, Interclass correlation coefficient 0.860). Responsiveness analysis showed good discriminative ability (AUC 0.788). Patients diagnosed more than 5 years ago reported a good HRQoL compared with the Dutch reference population, but experienced residual fatigue and emotional problems. Patients who underwent recent treatment reported a lower HRQoL and problems in several domains. In conclusion, we developed an ACC-specific HRQoL questionnaire with good psychometric properties.

Identifiants

pubmed: 35326518
pii: cancers14061366
doi: 10.3390/cancers14061366
pmc: PMC8946128
pii:
doi:

Types de publication

Journal Article

Langues

eng

Références

J Natl Cancer Inst. 1993 Mar 3;85(5):365-76
pubmed: 8433390
Cochrane Database Syst Rev. 2013 Mar 28;(3):CD007730
pubmed: 23543556
BMC Health Serv Res. 2013 Jun 11;13:211
pubmed: 23758898
J Endocr Soc. 2020 Apr 01;4(5):bvaa040
pubmed: 32342024
Health Qual Life Outcomes. 2009 Dec 23;7:102
pubmed: 20030832
Acta Oncol. 2018 Oct;57(10):1381-1391
pubmed: 29912607
Biometrics. 1977 Mar;33(1):159-74
pubmed: 843571
N Engl J Med. 2012 Jun 7;366(23):2189-97
pubmed: 22551107
J Adv Nurs. 2008 Apr;62(1):107-15
pubmed: 18352969
Curr Oncol Rep. 2017 Feb;19(2):12
pubmed: 28220450
J Clin Epidemiol. 2010 Jul;63(7):737-45
pubmed: 20494804
Eur J Cancer. 2013 Jul;49(11):2579-86
pubmed: 23561851
Cancers (Basel). 2019 Oct 08;11(10):
pubmed: 31597261
J Patient Rep Outcomes. 2018 Sep 15;2:42
pubmed: 30294712
Eur J Endocrinol. 2018 Oct 01;179(4):G1-G46
pubmed: 30299884
Eur J Cancer. 2011 Sep;47(14):2188-94
pubmed: 21621408
Ann Oncol. 2020 Nov;31(11):1476-1490
pubmed: 32861807
Eur J Cancer. 2002 Aug;38(12):1611-4
pubmed: 12142050

Auteurs

Rebecca V Steenaard (RV)

Department of Internal Medicine, Máxima MC, 5631 BM Eindhoven/Veldhoven, The Netherlands.
CAPHRI School for Public Health and Primary Care, Ageing and Long-Term Care, Maastricht University, 6229 HX Maastricht, The Netherlands.
Department of Research, Netherlands Comprehensive Cancer Organization (IKNL), 3511 DT Utrecht, The Netherlands.

Thomas M A Kerkhofs (TMA)

Department of Internal Medicine, Division of Medical Oncology, Maastricht University Medical Center+, 6229 HX Maastricht, The Netherlands.

Myrte Zijlstra (M)

Department of Research, Netherlands Comprehensive Cancer Organization (IKNL), 3511 DT Utrecht, The Netherlands.
Department of Internal Medicine, St. Jans Gasthuis, 6001 BE Weert, The Netherlands.
Netherlands Association for Palliative Care (PZNL), 3511 DT Utrecht, The Netherlands.

Floortje Mols (F)

Department of Research, Netherlands Comprehensive Cancer Organization (IKNL), 3511 DT Utrecht, The Netherlands.
Department of Medical and Clinical Psychology, Tilburg University, 5037 AB Tilburg, The Netherlands.

Michiel N Kerstens (MN)

Department of Internal Medicine, University Medical Center Groningen, University of Groningen, 9713 GZ Groningen, The Netherlands.

Henry J L M Timmers (HJLM)

Department of Internal Medicine, Radboud University Medical Center, 6525 GA Nijmegen, The Netherlands.

Rachel S van Leeuwaarde (RS)

Department of Endocrine Oncology, University Medical Center Utrecht, 3584 CX Utrecht, The Netherlands.

Koen M A Dreijerink (KMA)

Department of Internal Medicine, Amsterdam University Medical Centers, Location VUMC, 1081 HV Amsterdam, The Netherlands.

Elisabeth M W Eekhoff (EMW)

Department of Internal Medicine, Amsterdam University Medical Centers, Location VUMC, 1081 HV Amsterdam, The Netherlands.

Els J M Nieveen van Dijkum (EJM)

Department of Surgery, Cancer Center Amsterdam, Amsterdam University Medical Centers, 1081 HV Amsterdam, The Netherlands.

Eleonora P M Corssmit (EPM)

Department of Endocrinology, Leiden University Medical Center, 2333 ZA Leiden, The Netherlands.

Ellen Kapiteijn (E)

Department of Medical Oncology, Leiden University Medical Center, 2333 ZA Leiden, The Netherlands.

Marjolein N T Kremers (MNT)

CAPHRI School for Public Health and Primary Care, Ageing and Long-Term Care, Maastricht University, 6229 HX Maastricht, The Netherlands.
Department of Internal Medicine, St. Jans Gasthuis, 6001 BE Weert, The Netherlands.

Richard A Feelders (RA)

Department of Endocrinology, Erasmus Medical Center, 3015 CA Rotterdam, The Netherlands.

Harm R Haak (HR)

Department of Internal Medicine, Máxima MC, 5631 BM Eindhoven/Veldhoven, The Netherlands.
CAPHRI School for Public Health and Primary Care, Ageing and Long-Term Care, Maastricht University, 6229 HX Maastricht, The Netherlands.
Department of Internal Medicine, Division of General Internal Medicine, Maastricht University Medical Center+, 6229 HX Maastricht, The Netherlands.

Classifications MeSH